The Chief of the Egypt Healthcare Authority discusses with the Chief of AstraZeneca Egypt the support of cancer patients and individuals with rare diseases and enhancing access to healthcare services in remote areas through telemedicine technology.
Chief of the Egypt Healthcare Authority: "We are actively discussing ongoing cooperation with AstraZeneca in green healthcare projects to enhance patient safety and environmental sustainability, and the widespread use of artificial intelligence technologies for early disease diagnosis, including cancer and rare diseases."
Chief of the Egypt Healthcare Authority: "We are collaborating with AstraZeneca to support the operation of the Virtual Care Hospital in Ismailia after completing the electronic infrastructure setup, to provide high-quality remote consultations and diagnostics to serve strategic and remote areas."
Chief of the Egypt Healthcare Authority: "We are discussing the establishment of an Innovation Hub with AstraZeneca using artificial intelligence to improve healthcare quality, increase service efficiency, make healthcare accessible to all, support medical innovation, reduce costs, and enhance interactions between patients and healthcare providers."
Chief of the Egypt Healthcare Authority: "Our cooperation with AstraZeneca includes training healthcare staff and establishing national offices for drugs and diseases, focusing on cancer and rare diseases, and offering new services such as genetic analysis of drugs to ensure their effectiveness and safety."
Chief of the Egypt Healthcare Authority: "We are exploring collaboration with AstraZeneca in the 'Cancer Care Africa' initiative to care for cancer patients in Africa, where the Authority will play a key role in enhancing care quality through training healthcare staff, conducting health surveys, and organizing awareness campaigns."
Chief of the Egypt Healthcare Authority: "We are discussing initiatives with AstraZeneca for early detection of non-communicable diseases, notably kidney failure, and studying their impact on environmental sustainability by reducing medical resource consumption, lowering pollution, and maintaining public health."
Chief of AstraZeneca Egypt: "I appreciate the success of the partnership model between the public sector represented by the Egypt Healthcare Authority and the private sector represented by AstraZeneca in building a strong, flexible, effective, and sustainable health system to achieve Egypt's vision for sustainable health development by 2030."
Chief of AstraZeneca Egypt: "The Egypt Healthcare Authority has achieved unprecedented development in the healthcare sector, and we are proud to continue our cooperation to provide the best possible health services and care."
Dr. Ahmed El Sobky, Chief of the Egypt Healthcare Authority and General Supervisor of the Comprehensive Health Insurance and Decent Life projects at the Ministry of Health and Population, met with Dr. Hatem El Wardani, Chief of AstraZeneca Egypt, Dr. Mohamed Amin, Chief of Market Support, Dr. Ahmed Qashta, Chief of Government and Institutional Relations, and Engineer Laila Sulaiman, Chief of Digital Development and Information Technology, at the Authority's headquarters in Cairo.
"The meeting discussed the achievements of the cooperation between the Egypt Healthcare Authority and AstraZeneca in various joint files, including supporting cancer patients and individuals with rare diseases, enhancing access to healthcare services in remote areas through telemedicine technology, green healthcare projects, activating the virtual hospital in Ismailia, establishing an innovation center using artificial intelligence technologies, in addition to initiatives for early detection of non-communicable diseases, and future cooperation directions."
"At the start of the meeting, Dr. Ahmed El Sobky welcomed the Chief of AstraZeneca Egypt, valuing the ongoing and fruitful cooperation with the Egypt Healthcare Authority and emphasizing the importance of enhancing this cooperation in shared fields to serve healthcare and achieve future goals."
"Dr. El Sobky highlighted the importance of continued cooperation with AstraZeneca in green healthcare projects aimed at enhancing patient safety and environmental sustainability, as well as expanding the use of artificial intelligence technologies for early disease diagnosis, including cancers and rare diseases."
"Dr. El Sobky added that the cooperation with AstraZeneca includes supporting the operation of the Virtual Care Hospital in Ismailia after setting up the electronic infrastructure, aiming to provide high-quality remote consultations and diagnostics to serve citizens in strategic and remote areas."
"The Chief of the Egypt Healthcare Authority pointed out that the cooperation with AstraZeneca also includes establishing an Innovation Hub using artificial intelligence to enhance healthcare quality, increase service efficiency, make healthcare accessible to all, support medical innovation, reduce costs, and enhance interactions between patients and healthcare providers."
"Dr. El Sobky explained that the cooperation involves training healthcare staff, establishing national offices for drugs and diseases, focusing on cancers and rare diseases, and providing new services such as genetic drug analysis to ensure their effectiveness and safety."
"Dr. El Sobky continued that the Egypt Healthcare Authority is exploring cooperation with AstraZeneca in the 'Cancer Care Africa' initiative to care for cancer patients in Africa, where the Authority will play a key role in enhancing care quality through training healthcare staff, conducting health surveys, and organizing awareness campaigns, as well as collaborating in initiatives for early detection of non-communicable diseases, notably kidney failure, and studying their impact on environmental sustainability by reducing medical resource consumption, lowering pollution, and maintaining public health."
"Dr. Hatem El Wardani, Chief of AstraZeneca Egypt, expressed his pleasure in being with the leadership of the Egypt Healthcare Authority, noting that the cooperation between the Egypt Healthcare Authority and AstraZeneca aims to achieve a shared vision of building a more sustainable healthcare system for individuals, the community, and the environment."
"Dr. El Wardani emphasized the importance of this cooperation in areas of environmental sustainability, such as the inauguration of the green field hospital on the sidelines of the COP27 Climate Conference, as well as in the field of early detection of non-communicable diseases, such as chronic kidney disease within the Kidney Initiative, through which an early detection campaign was launched."
"Dr. El Wardani explained that the partnership seeks to enhance the efficiency of the health system by expanding the use of artificial intelligence technologies for early disease diagnosis, including cancers and rare diseases, and supporting the generation and use of health data, in line with Egypt's Vision 2030 for sustainable health."
"He praised the success of the partnership model between the public sector, represented by the Egypt Healthcare Authority, and the private sector, represented by AstraZeneca, in building a strong, flexible, effective, and sustainable health system, noting that the Egypt Healthcare Authority has achieved unprecedented development in the healthcare sector, which enhances AstraZeneca's pride in continuing cooperation to provide the best possible health services and care."
"Attending the meeting from the side of the Egypt Healthcare Authority were: Dr. Amir El Tolwani, Executive Director of the Authority; Dr. Ahmed Hammad, Advisor to the Chief of the Authority for Policies and Health Systems and General Manager of the General Administration of the Technical Office for the Chief of the Authority; Dr. Sherif Kamal, Advisor to the Chief of the Authority for Pharmaceutical Affairs and Drug Management; Dr. Fathy Shams El Din, Media Advisor to the Chief of the Authority and General Supervisor of the Media; Dr. Shaimaa Abdullah, Deputy General Manager of the General Administration of the Technical Office for the Chief of the Authority; Dr. Maha Saeed, Director of the Drug Vigilance Unit; and Dr. Nashwa Gouda, Member of the Technical Office for the Chief of the Authority."